Tag
A phase 1 trial of XmAb18968, a CD38-CD3 bispecific antibody, demonstrates safety and encouraging efficacy in heavily pretreated relapsed/refractory AML and T-ALL patients, highlighting a novel therapeutic avenue.
The EPCORE CLL-1 trial evaluated epcoritamab, a CD3×CD20 bispecific antibody, in patients with Richter transformation. While the 47.6% overall response rate narrowly missed the 50% target, the results highlight a significant therapeutic sig
A Phase 1 trial of SOR102, a first-in-class oral bispecific antibody targeting TNF and IL-23, demonstrates favorable safety and preliminary clinical activity in patients with ulcerative colitis, suggesting a potential shift toward localized
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
Phase 3 HARMONi‑6: ivonescimab + paclitaxel/carboplatin increased median PFS to 11.1 vs 6.9 months (HR 0.60, P<0.0001) and improved ORR versus tislelizumab+chemo in first‑line advanced squamous NSCLC, with low major bleeding (≥ grade 3,
